Publications by authors named "Matthew Frigault"

Claim this Profile
P
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
Tim Meyer, Richard S Finn, Mitesh Borad, Amit Mahipal, Julien Edeline, Matthew Frigault

J Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Infiltrating Lymphocyte Therapy Generated from Melanoma Brain Metastasis: Proof-of-Concept for CNS-Derived Cellular Immunotherapy.
Eric P Grewal, Samuel J Steuart, Baolin Liu, Hongyan Xie, Derek N Effiom, Matthew J Frigault

Neuro Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.
Joshua N Gustine, John A Scaringi, Fabian Bauer, Diana D Cirstea, Andrew R Branagan, Matthew J Frigault

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safe and Effective Addition of Ruxolitinib to Graft-versus-host Prophylaxis in Older Adults Undergoing Reduced-intensity Allogeneic Hematopoietic Cell Transplantation.
Christof C Smith, Jooho Chung, Areej El-Jawahri, Matthew J Frigault, Steven McAfee

Transplant Cell Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies.
Frederick L Locke, Sarah Nikiforow, Matthew J Frigault, David G Maloney, Marco Davila

Transplant Cell Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy.
Leon D Kaulen, Maria Martinez-Lage, Jeremy S Abramson, Philipp Karschnia, Sofia Doubrovinskaia, Matthew J Frigault

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to <[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>.
Melissa R Hines, Tristan E Knight, Kevin O McNerney, Mark B Leick, Tania Jain, Matthew J Frigault

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy.
Osnat Itzhaki Ben Zadok, Panagiotis Simitsis, Caron Jacobson, Omar Nadeem, Matthew J Frigault

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transdifferentiation From Multiple Myeloma to Myeloid Sarcoma in the Setting of CAR T-Cell Therapy.
Diana Cirstea, Kathleen Gallagher, Maxx King, Paola Dal Cin, Mark J Sloan, Matthew Frigault

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting.
Bradley D Hunter, Matthew Lunning, Mazyar Shadman, Sairah Ahmed, Jeremy S Abramson, Matthew J Frigault

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy.
Jessica S Little, Angelica Medina Pena, E Bridget Kim, Andrew J Yee, Omar Nadeem, Matthew J Frigault

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study.
Matthew J Frigault, Richard T Maziarz, Jae H Park, Aleksandr Lazaryan, Nirav N Shah

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma.
Hazim S Ababneh, Andrea K Ng, Joshua Wan, Tyler Walburn, Lin Zhu, Matthew J Frigault

Int J Radiat Oncol Biol Phys· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.
Laura Samples, Hossein Sadrzadeh, Matthew J Frigault, Caron A Jacobson, Mehdi Hamadani

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells.
Frederick L Locke, Zahra Mahmoudjafari, Partow Kebriaei, Rebecca A Gardner, Matthew J Frigault

Transplant Cell Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment.
Viktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, Mark B Leick, Md Raihan Chowdhury, Matthew J Frigault

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma.
Joshua N Gustine, Andrew R Branagan, Diana D Cirstea, Farah Rexha, Ryan Han, Matthew J Frigault

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges.
Leyla Shune, Matthew J Frigault, Peter A Riedell

J Immunother Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells.
Rishab Ramapriyan, Fred G Barker, Leland G Richardson, Jing Sun, Gust Vandecandelaere, Matthew J Frigault

Neuro Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokines and immune effector cell therapy.
Alexandra Haugh, Matthew J Frigault

Best Pract Res Clin Haematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma.
Matthew J Frigault, Ning Yao, Trisha R Berger, Marc Wehrli, Kathleen M E Gallagher

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.
Zachariah DeFilipp, Haesook T Kim, Laura W Knight, Suzanne M O'Connor, Shilton E Dhaver, Matthew J Frigault

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.
Charlotte E Graham, Roser Velasco, Ana Alarcon Tomas, Orla P Stewart, Guillaume Dachy, Matthew J Frigault

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal, Matthew J Frigault

Leukemia· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.
Daniel J Landsburg, Matthew J Frigault, Michael Heim, Stephen Ronan Foley, Brian Hill

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis